Thermal Decomposition of Some Cardiovascular Drugs (Telmisartane, Cilazapril and Terazosin HCL)

Fluorimetric Methods for the Determination of Terazosin HCl in Drug Substance and Dosage Forms

Determination of terazosin hydrochloride dihydrate (TRZ) in drug substance and tablets was studied by fluorimetric techniques. The fluorimetric methods are based on: (1) measurement of the native fluorescence of the drug in water at 750 nm after excitation at 330 nm. (2) sensitizing the native fluorescence by formation a binary complex of drug with aqueous uranyl acetate (0.1% w/v) at the same ...

Thermoanalytical investigation of terazosin hydrochloride.

PURPOSE Thermal analysis (TGA, DTG and DTA) and differential scanning calorimetry (DSC) have been used to study the thermal behavior of terazosin hydrochloride (TER). METHODS Thermogravimetric analysis (TGA/DTG), differential thermal analysis (DTA) and differential scanning calorimetry (DSC) were used to determine the thermal behavior and purity of the used drug. Thermodynamic parameters such...

Enalapril enhances the anticonvulsant activity of lamotrigine in the test of maximal electroshock.

BACKGROUND The aim of this study was to find out whether angiotensin-converting enzyme (ACE) inhibitors, enalapril and cilazapril, affect the anticonvulsant action of some second-generation antiepileptics, lamotrigine (LTG), topiramate (TPM) and oxcarbazepine (OXC). METHODS The effects of ACE inhibitors on antiepileptic drugs were examined in the mouse model of maximal electroshock. RESULTS...

Structure characterization of terazosin drug using mass spectrometry and thermal analyses techniques in comparison with semi-empirical molecular orbital (MO) calculations

Month/Year of Review: May 2014 Date of Last Review: November 2012 PDL Classes: BPH Source Document: OSU College of Pharmacy Current Status of PDL Class: Preferred Agents: DOXAZOSIN MESYLATE, FINASTERIDE, TAMSULOSIN HCL, TERAZOSIN HCL

Previous Conclusions and Recommendation:  Evidence does not support a difference in efficacy/effectiveness  Evidence does not support a difference in harms/adverse events  Tadalfil demonstrated improvements in urinary symptoms compared to placebo in patients with lower urinary tract symptoms, but demonstrated no difference in post void residual volume or urinary flow rate.  Tadalafil is als...